# Immorta Bio finishes AI senolytic peptide trials

> Immorta Bio completes preclinical studies for AI-designed senolytic peptide.
- Title: Immorta Bio finishes AI senolytic peptide trials · RuntimeWire
- Summary: Immorta Bio completes preclinical studies for AI-designed senolytic peptide. Immorta Bio has completed preclinical studies for an AI-designed senolytic…
- Keywords: immorta bio, senolytic peptide, ai-designed, preclinical studies, immune cells, senescent cells, technology, Immorta, Bio, finishes, senolytic, peptide
- Source: RuntimeWire — https://runtimewire.com/article/immorta-bio-ai-designed-senolytic-peptide-preclinical
- Author: RuntimeWire
- Published: 2026-10-12T14:50:46.647+00:00
- Read time: 1 min
- Topics: immorta bio, senolytic peptide, ai-designed, preclinical studies, immune cells, senescent cells, technology, ai
## Immorta Bio completes preclinical studies
Immorta Bio has completed planned preclinical studies for SenoMune-0257, an AI-designed nine-amino-acid peptide.
## Peptide targets senescent cells
The peptide aims to train immune cells to remove senescent cells through immune-based senolytic therapy.
## Next step: human testing
Immorta Bio plans human testing to test both the biology and its product strategy for immune-based senolytic therapy.
## Key takeaway

Immorta Bio has completed preclinical studies for an AI-designed senolytic peptide to train immune cells to remove senescent cells.